Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (8278)	5/6/2003 9:09:02 PM
From: Harold Engstrom	Respond to of 52153

>>They claim that Q1 is historically slow for cholesterol drugs, although I'm not sure why that should be so.<< Pre-bbq season, post-holiday season...?

To: Biomaven who wrote (8278)	5/8/2003 9:15:59 AM
From: robert miller	Read Replies (1) \| Respond to of 52153

They have 3 patents on Niaspan and 2 pending. I don't have any qualifications to discuss the quality of the patents. They are working on a low flush Niaspan scheduled for 2007. I don't know but my guess it uses the expanding material they licensed from Purdue Univ. They are increasing the sales force. It should be up to 600 by year end. It is true the first quarter results were inflated by the one time adjustment, but excluding this it was 8 cents which was a figure I was happy with. bob